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Ribonucleotide reductase (RNR) is responsible for converting ribonucleotides
to deoxyribonucleotides, which are the building blocks of DNA. The enzyme
is present in all life forms as well as in some large DNA viruses such as
herpesviruses. The -herpesviruses and -herpesviruses encode two class Ia
RNR subunits, R1 and R2, while the -herpesvirus subfamily only encode an
inactive R1 subunit. Here, the crystallization of the R2 subunit of RNR encoded
by the ORF60 gene from the oncovirus Kaposi’s sarcoma-associated
-herpesvirus (KSHV) is reported. These are the first crystals of a viral R2
subunit; the use of in situ proteolysis with chymotrypsin and the addition of
hexamine cobalt(III) chloride that were necessary to obtain crystals are
described. Optimization of the crystallization conditions yielded crystals that
diffracted to 2.0 A˚ resolution. The crystals belonged to space group P21, with
unit-cell parameters a = 63.9, b = 71.2, c = 71.8 A˚,  = 90,  = 106.7,  = 90. The
data set collected was 95.3% complete, with an Rmerge of 9.6%. There are two
molecules in the asymmetric unit, corresponding to a solvent content of 43.4%.
1. Introduction
The enzyme ribonucleotide reductase (RNR) is present in all life
forms as well as in some large DNA viruses such as herpesviruses
(Eklund et al., 2001). This allosterically regulated enzyme is respon-
sible for the reduction of all four ribonucleotides to their corre-
sponding deoxyribonucleotides (dNTPs), which are the building
blocks of DNA. This reaction involves a free radical (Eklund et al.,
2001) and the activity of RNR regulates the cellular levels of the
dNTP pool, ensuring that precise DNA replication and repair occurs.
Based on the source of the radical cofactor used in the reductive
reaction, RNRs have been divided into three classes: I, II and III.
Class I is further divided into subclasses Ia and Ib. Class I RNRs are
composed of a heterotetramer, which is in turn composed of two
homodimers of the R1 and R2 subunits. The R1 subunit contains the
active site as well as the sites for allosteric regulation. The R2 subunit
contains a di-iron site, which generates a free radical by the reductive
cleavage of molecular oxygen. The free radical is subsequently
transferred to the R1 subunit, activating the nucleotide substrate for
catalysis. In eukaryotes the activity of the RNR enzyme is cell-cycle
dependent and reaches its highest level during the S phase, when
DNA synthesis and replication occur (Nordlund & Reichard, 2006).
The regulation of the R2 subunit takes place on a transcriptional level
as well as by protein degradation and this regulation is rate-limiting
for the activity of the RNR holoenzyme. The R2 gene is normally not
transcribed in resting cells. However, certain events, such as DNA
repair and synthesis of mitochondrial DNA, require that the synthesis
of deoxyribonucleotides also occurs in resting cells. Thus, in order to
synthesize dNTPs in response to DNA damage, quiescent cells are
able to synthesize another cellular R2, p53R2, which may form a
functional enzyme together with cellular R1 (Eklund et al., 2001;
Nordlund & Reichard, 2006). Its name reflects the fact that it is
controlled/regulated by the transcription factor and the tumour
suppressor p53. In addition, viral replication in infected cells may also
trigger the production of dNTPs.
Herpesviruses represent one of the best characterized members of
the large family of DNA viruses that are known to cause disease in
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humans as well as in other vertebrates (Boehmer & Nimonkar, 2003).
Members of the Herpesviridae family include human pathogens such
as herpes simplex virus, varicella zoster virus, cytomegalovirus,
Epstein–Barr virus (EBV) and Kaposi’s sarcoma-associated herpes-
virus (KSHV). Owing to differences in genomic content, organization
and cellular tropism, mammalian herpesviruses may be classified as
belonging to one of three subfamilies: the -, - and -subfamilies
(Lembo & Brune, 2009). Interestingly, the members of the - and
-subfamilies encode two class Ia subunits (R1 and R2) of the RNR
enzyme, while the -herpesviruses encodes an inactive R1 subunit
(Lembo & Brune, 2009). The presence of a fully functional RNR in
the - and -subfamilies, despite the host already encoding a func-
tional enzyme of its own, indicates that the virus may have evolved
to ensure a sufficient supply of nucleotides even if the host is in a
quiescent state. The oncovirus KSHV, together with EBV, belongs to
the -subfamily of human herpesviruses. The R2 subunit of herpes-
viruses, encoded by the ORF60 gene in KSHV, shares low sequence
identity to other R2s of bacterial and eukaryotic origin (Nordlund &
Reichard, 2006). To date, no structure of an R2 subunit from a
herpesvirus has been published. An interesting feature of the amino-
acid sequence is that a glutamate, Glu64, is found in the position that
is usually occupied by a metal-coordinating aspartate in other R2s.
Structural studies of this enzyme are important as the protein will
serve as a potential drug target for the treatment of herpesviral
infections and associated forms of cancer. Here, the crystallization of
the R2 subunit, encoded by the ORF60 gene, from KSHV using an in
situ proteolysis approach is described. This approach was essential in
obtaining diffraction-grade crystals.
2. Materials and methods
2.1. Cloning, expression and purification
The ORF60 gene encoding residues 1–305 was cloned as described
previously (Uetz et al., 2006) and subsequently subcloned using the
Gateway system (Invitrogen, Carlsbad, California, USA) into the
pTH27 expression vector (Hammarstro¨m et al., 2006). The vector
encodes a polypeptide consisting of the ORF60 protein with an
N-terminal extension (MGPHHHHHHLESTSLYKKAGS). This
N-terminal extension encompasses an attB1 site for the Gateway
recombination event and a His tag to facilitate protein purification
(Hammarstro¨m et al., 2006).
The ORF60 protein was overexpressed in Escherichia coli BL21
(DE3) cells (Stratagene, Cedar Creek, Texas, USA). A single colony
was used to inoculate an overnight culture of 30 ml Luria–Bertani
(LB) medium containing 50 mg ml1 carbenicillin. 10 ml of the
overnight culture was subsequently added to a larger volume (1 l) of
Terrific Broth (TB) medium supplemented with 50 mg ml1 carbeni-
cillin. The cells were grown at 310 K until an OD600 nm of approxi-
mately 1.0 was reached. At this point, the temperature was reduced to
291 K and ORF60 protein expression was induced by the addition of
isopropyl -d-1-thiogalactopyranoside (IPTG) to a final concentra-
tion of 0.1 mM and left overnight in the shaker-incubator. The cells
were then harvested by centrifugation and the pellet was resuspended
in lysis buffer [50 mM sodium phosphate pH 8.0, 500 mM NaCl,
10%(v/v) glycerol, 10 mM imidazole pH 8.0, 10 U ml1 DNaseI
(Roche), 0.08 mg ml1 lysozyme, one tablet of Complete EDTA-free
Protease Inhibitor cocktail (Roche) per 50 ml and 0.5 mM TCEP]
before being frozen at 253 K. For purification, the frozen cell resus-
pension was thawed and sonicated. The cell lysate was then centri-
fuged at 50 000g for 40 min and the supernatant was subsequently
passed through a 0.22 mm filter to remove cell debris. Purification of
the ORF60 protein was carried out on an A¨KTA Xpress system
(GE Healthcare, Uppsala, Sweden) using immobilized metal-affinity
chromatography (IMAC) and gel filtration. The crude extract was
loaded onto a 5 ml HisTrap FF column (GE Healthcare) pre-
equilibrated in buffer 1 [50 mM sodium phosphate pH 8.0, 500 mM
NaCl, 10%(v/v) glycerol, 10 mM imidazole pH 8.0 and 0.5 mM
TCEP]. In addition to washing with buffer 1, a second wash was
performed using buffer 1 with 70 mM imidazole pH 8.0. ORF60 was
then eluted with elution buffer [the same as buffer 1 but with 500 mM
imidazole pH 8.0 and one tablet of Complete EDTA-free Protease
Inhibitor (Roche) per 50 ml]. The fractions that contained the protein
of interest from the IMAC elution were pooled prior to loading onto
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Figure 1
(a) Gel-filtration chromatogram of ORF60 eluted from a HiLoad 26/60 Superdex 200 gel-filtration column. The fractions corresponding to the major peak (ORF60) were
pooled and concentrated and used in crystallization experiments. (b) Coomassie-stained SDS–PAGE (4–12%) gel of ORF60 protein eluted from the gel-filtration column,
showing the typical purity of the protein sample used for crystallization experiments. The left lane contains protein molecular-weight markers (kDa). The ORF60 protein
elutes at a approximate molecular weight of 31 kDa; however, mass spectrometry confirmed the exact molecular weight based on the full-length construct to be closer to
37 kDa.
a HiLoad 26/60 Superdex 200 gel-filtration column (GE Healthcare)
pre-equilibrated in gel-filtration buffer [20 mM HEPES pH 7.5,
300 mM NaCl, 10%(v/v) glycerol and 0.5 mM TCEP]. The fractions
that contained the ORF60 protein (Fig. 1a) were pooled and
concentrated using an Amicon Ultra centrifugal filter device (Milli-
pore, Bedford) with a 10 kDa molecular-weight cutoff. The purity of
the protein was investigated by SDS–PAGE (Fig. 1b) and its mole-
cular mass of 37 442.98 Da was verified by mass spectrometry. The
protein appeared on the SDS–PAGE gel as a monomer of 31 kDa.
The reason for the discrepancy in the molecular weight between the
mass spectrum and the SDS–PAGE experiments is currently un-
known. The protein concentration was determined by UV absorption
at 280 nm using a spectrophotometer, based on the theoretically
calculated absorption molar coefficient of 36 120 M1 cm1.
2.2. Crystallization
Preliminary crystallization attempts using the sitting-drop vapour-
diffusion technique were performed at 277 and 293 K with the
ORF60 protein at a concentration of 10 mg ml1 (in gel-filtration
buffer; 20 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol). Initial
crystallization screening was conducted using a Phoenix crystal-
lization robot (Art Robbins Instruments, Sunnyvale, California,
USA). 200 nl drops (100 nl protein solution mixed with 100 nl
reservoir solution) were equilibrated against a reservoir that con-
tained a larger volume (70 ml) of screening solution. Four screens
from Qiagen set up at two different temperatures (277 and 293 K)
were used for initial screening: Classics Suite, JCSG+ Suite, PEGs
Suite and PEGs II Suite. However, these 288 different conditions did
not yield any crystal hits. Therefore, in situ proteolysis (Dong et al.,
2007) was undertaken in an attempt to promote crystal formation.
Chymotrypsin was mixed with the ORF60 protein to a final con-
centration of 0.1 mg ml1 immediately before the crystallization-drop
setups were repeated with the JCSG+ screen. After 2 d, we obtained
crystal rods (Fig. 2a) in 0.2 M MgCl2, 0.1 M Tris–HCl pH 8.5 and
20%(w/v) PEG 8000. However, optimization around this condition
failed to produce thicker crystals that were suitable for detailed
structural determination. The crystal rods only diffracted to 3.8 A˚
resolution (Fig. 2a). Using Additive Screen (Hampton Research,
Aliso Viejo, California, USA), we identified 0.1 M hexamine
cobalt(III) chloride {[Co(NH3)6]Cl3} as an additive that induced the
formation of thicker crystals (Fig. 2b). Further optimization using the
hanging-drop vapour-diffusion method produced three-dimensional
crystals after 2 d that diffracted to 2.0 A˚ resolution. The optimized
reservoir solution contained 14%(w/v) PEG 8000, 0.2 M MgCl2,
0.1 M Tris–HCl pH 8.2. In addition to 20 mM HEPES pH 7.5, 300 mM
NaCl and 10% glycerol, the protein solution contained 0.1 mg ml1
chymotrypsin and 0.1 M hexamine cobalt(III) chloride.
2.3. X-ray data collection and processing
Crystals were cryoprotected for 1–2 s in 20–25%(v/v) glycerol in
14%(w/v) PEG 8000, 0.2 M MgCl2, 0.1 M Tris–HCl pH 8.2 prior to
cryocooling in liquid nitrogen. X-ray diffraction data were collected
at 100 K from a single ORF60 crystal at a wavelength of 0.97 A˚ on
ID29 at the ESRF, Grenoble, France using an ADSC Q315R CCD
detector. The crystal-to-detector distance was 313 mm and an oscil-
lation range of 0.6 was used, resulting in the collection of a total of
200 images. The diffraction data were processed and scaled using
MOSFLM (Leslie, 1992) and SCALA (Evans, 1993) from the CCP4
suite of programs (Collaborative Computational Project, Number 4,
1994). The space group was determined to be P21, with unit-cell
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Figure 2
Crystals of ORF60 from KSHV. (a) Crystal rods that grew after in situ proteolysis
with chymotrypsin. The crystal dimensions are approximately 0.18  0.02 
0.02 mm. (b) Addition of hexamine cobalt(III) chloride to the crystallization drop
resulted in the formation of thicker better diffracting crystals (2.0 A˚). The crystals
are presumably a truncated form of ORF60 that was produced after proteolytic
cleavage by chymotrypsin. The crystal dimensions are approximately 0.7  0.05 
0.02 mm.
Table 1
Data-collection and processing statistics.




Unit-cell parameters (A˚, ) a = 63.9, b = 71.2, c = 71.8,
 = 90,  = 106.7,  = 90
Resolution range (A˚) 71.25–2.00 (2.11–2.00)
Unique observations 39715 (5268)
Redundancy 2.4 (1.9)
Completeness (%) 95.3 (87.2)
Rmerge† (%) 0.096 (0.616)
hI/(I)i 5.9 (2.2)
Matthews coefficient VM (A˚
3 Da1) 2.17
Molecules in the asymmetric unit 2









i IiðhklÞ, where Ii(hkl) is the intensity of
reflection hkl and hI(hkl)i is the mean intensity of reflection hkl.
parameters a = 63.91, b = 71.20, c = 71.81 A˚,  = 90,  = 106.7,  = 90.
The data-collection statistics are summarized in Table 1.
3. Results and discussion
In this paper, we report the successful expression, purification and
crystallization of the first viral RNR R2 subunit (ORF60) from the
Kaposi’s sarcoma-associated herpesvirus. We collected high-
resolution X-ray diffraction data to 2.0 A˚ resolution from crystals
that were obtained after in situ proteolytic treatment of the ORF60
protein (Dong et al., 2007). We believe that the in situ proteolysis with
chymotrypsin was responsible for obtaining a crystallizable trunca-
tion of ORF60, since the 288 crystallization trials set up at two
different temperatures without chymotrypsin failed to produce any
crystal hits. However, structure determination of ORF60 will be
necessary to confirm this. The crystals obtained by chymotrypsin
treatment belonged to space group P21, with unit-cell parameters
a = 63.91, b= 71.20, c= 71.81 A˚, = 90, = 106.7,  = 90. The data set
is 95.3% complete, with an Rmerge of 9.6%. Computations based on
the protein molecular weight indicate the presence of two molecules
in the asymmetric unit, corresponding to a Matthews coefficient
(Matthews, 1968) VM of 2.17 A˚
3 Da1 and a calculated solvent
content of 43.4%. These values are within the expected range for
typical protein crystals. Further attempts to determine the structure
of ORF60 by molecular replacement are currently under way using
search models that show the highest sequence identity to ORF60
according to the RCSB search option: PDB codes 1jk0 (27%
sequence identity; Voegtli et al., 2001), 3hf1 (26% sequence identity;
Smith et al., 2009), 2vux (26% sequence identity; M. Welin et al.,
unpublished work) and 1h0n (26% sequence identity; Strand et al.,
2002). The ORF60 structure may be of great value in the pursuit of
potential drug targets for the treatment of herpesviral infections and
associated forms of cancer.
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